Myriad Genetics, Inc. (MYGN)
5.54
+1.33
(+31.59%)
USD |
NASDAQ |
Oct 20, 16:00
5.64
+0.10
(+1.81%)
Pre-Market: 08:02
Myriad Genetics Research and Development Expense (TTM) : 105.80M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 105.80M |
| March 31, 2026 | 106.40M |
| December 31, 2025 | 106.80M |
| September 30, 2025 | 111.00M |
| June 30, 2025 | 111.30M |
| March 31, 2025 | 112.80M |
| December 31, 2024 | 110.20M |
| September 30, 2024 | 101.50M |
| June 30, 2024 | 97.00M |
| March 31, 2024 | 91.10M |
| December 31, 2023 | 88.70M |
| September 30, 2023 | 91.10M |
| June 30, 2023 | 87.60M |
| March 31, 2023 | 86.70M |
| December 31, 2022 | 85.40M |
| September 30, 2022 | 78.60M |
| June 30, 2022 | 76.90M |
| March 31, 2022 | 76.10M |
| December 31, 2021 | 78.00M |
| September 30, 2021 | 78.80M |
| June 30, 2021 | 79.70M |
| March 31, 2021 | 79.00M |
| June 30, 2020 | 77.20M |
| March 31, 2020 | 80.70M |
| December 31, 2019 | 82.40M |
| Date | Value |
|---|---|
| September 30, 2019 | 85.40M |
| June 30, 2019 | 85.20M |
| March 31, 2019 | 82.00M |
| December 31, 2018 | 79.10M |
| September 30, 2018 | 74.10M |
| June 30, 2018 | 70.80M |
| March 31, 2018 | 71.90M |
| December 31, 2017 | 71.00M |
| September 30, 2017 | 72.80M |
| June 30, 2017 | 74.40M |
| March 31, 2017 | 75.10M |
| December 31, 2016 | 74.70M |
| September 30, 2016 | 72.80M |
| June 30, 2016 | 70.60M |
| March 31, 2016 | 69.80M |
| December 31, 2015 | 69.27M |
| September 30, 2015 | 70.08M |
| June 30, 2015 | 75.49M |
| March 31, 2015 | 76.98M |
| December 31, 2014 | 73.70M |
| September 30, 2014 | 73.29M |
| June 30, 2014 | 66.97M |
| March 31, 2014 | 61.36M |
| December 31, 2013 | 61.58M |
| September 30, 2013 | 58.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Natera, Inc. | 787.38M |
| Sera Prognostics, Inc. | 12.27M |
| BioRestorative Therapies, Inc. | 9.374M |
| CareDx, Inc. | 79.87M |
| Exagen, Inc. | 6.466M |